EyePoint sells remaining rights to eye implant, pivots to tackle anti-VEGFs
EyePoint is selling off the remaining global rights to its intravitreal implant Yutiq to Alimera, another eye-focused biotech, for $82.5 million.
EyePoint Pharmaceuticals announced Thursday that Alimera will receive global rights to Yutiq except in China, Hong Kong, Taiwan, Macau and Southeast Asia. EyePoint, in 2018, granted an exclusive license to Ocumension Therapeutics, a Chinese biotech in those markets. EyePoint continues to receive royalties from those sales — and expects to keep them for at least the next decade.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.